讯飞医疗科技2025年中期报告

INTERIM REPORT2025 Contents目錄 Definition2Corporate Information6Management Discussion and Analysis9Other Information39Report on Review of Condensed Consolidated Financial Statements51Condensed Consolidated Statement of Profit or Loss andOther Comprehensive Income53Condensed Consolidated Statement of Financial Position54Condensed Consolidated Statement of Changes in Equity56Condensed Consolidated Statement of Cash Flows57Notes to the Condensed Consolidated Financial Statements58 Definition釋義 Corporate Information公司資料 NAME OF THE COMPANYCHINESE NAME Xunfei Healthcare Technology Co., Ltd. ENGLISH NAMEXunfei Healthcare Technology Co., Ltd. DIRECTORSEXECUTIVE DIRECTORDr. Tao Xiaodong(General Manager) NON-EXECUTIVE DIRECTORSDr. Liu Qingfeng(Chairman)Mr. Zhao ZhiweiMr. Duan Dawei INDEPENDENT NON-EXECUTIVE DIRECTORS Prof. Wang YangProf. Zhao HuifangMr. Tan Ching AUDIT COMMITTEEProf. Zhao Huifang(Chairwoman)Prof. Wang YangMr. Duan Dawei REMUNERATION COMMITTEE Prof. Zhao Huifang(Chairwoman)Mr. Zhao ZhiweiMr. Tan Ching NOMINATION COMMITTEEDr. Liu Qingfeng(Chairman)Prof. Zhao HuifangMr. Tan Ching (ESG) ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG)COMMITTEE Dr. Liu Qingfeng(Chairman)Dr. Tao XiaodongProf. Wang Yang JOINT COMPANY SECRETARIES Dr. Liu WeiMs. Yeung Siu Lam AUTHORISED REPRESENTATIVESDr. Tao XiaodongDr. Liu Wei HEAD OFFICE AND PRINCIPAL PLACE OFBUSINESS IN THE PRC 666 No. 666 Science and Innovation Road,Chengxiqiao Community Services Center, High-tech ZoneHefei City, Anhui ProvincePRC 33191922 PRINCIPAL PLACE OF BUSINESS IN HONG KONG Room 1922, 19/F, Lee Garden One33 Hysan AvenueCauseway BayHong Kong H1617 H SHARE REGISTRAR Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong 2506 STOCK CODE2506 https://www.iflyhealth.com/ COMPANY’S WEBSITEhttps://www.iflyhealth.com/ 8835 INDEPENDENT AUDITOR Deloitte Touche TohmatsuCertified Public AccountantsRegistered Public Interest Entity Auditors35/F, One Pacific Place88 QueenswayHong Kong Corporate Information公司資料 LEGAL ADVISORS TO OUR COMPANY 27 As to Hong Kong law:Clifford Chance27/F, Jardine HouseOne Connaught PlaceCentralHong Kong 13662805 As to PRC law:CM Law FirmRoom 2805, Plaza 66 Tower 2No. 1366 Nanjing West RoadShanghaiPRC 2920 COMPLIANCE ADVISOR Somerley Capital Limited20/F, China Building29 Queen’s Road CentralHong Kong PRINCIPAL BANKS 848 Huishang Bank Hefei High-Tech Zone BranchNo. 848 Changjiang West RoadShushan DistrictHefei, Anhui ProvincePRC 169 China Merchants Bank Hefei Sanxiaokou BranchCMB BuildingNo. 169 Funan RoadLuyang DistrictHefei, Anhui ProvincePRC Management Discussion and Analysis管理層討論與分析 2025AIAIAIGBC In the first half of 2025, a groundbreaking leap was made inthetraining and reasoning efficiency of domestic general-purpose large models, leading to the significant enhancementof the core capabilities of large models in the healthcare sectorandthe continuous optimization of medical AI applications.China has introduced a number of supportive policies and clearimplementationguidelines,promoting the deep integration ofAItechnology with such scenarios as public health,clinicalmedicine, and health management, and providing strong policysupport and broad market space for the Company to step up itspresence in the smart healthcare market. Driven by acceleratedtechnological innovation, policy support, and demand for high-qualitydevelopment in healthcare,the medical AI industryshowed a prosperous development trend. Leveraging medicallargemodel technology and the construction of a medicalknowledge base, the Company consistently maintains its leadingpositionin medical large models.Through ongoing upgradestoits AI-powered diagnostic assistant and health assistantproductseries with large model technology,the Companysatisfiedthe diversified needs of government,business andconsumers.This has enabled the creation of an AI-poweredproduct matrix tailored for GBC clients, enhancing governmentregulatory governance, improving hospital quality and efficiency,and empowering personal health management. Ultimately, theseeffortssolidify Xunfei Healthcare’s role in driving forward theglobal healthcare industry as a leader. Management Discussion and Analysis管理層討論與分析 2023— Asa pioneer in the innovative practice of medical artificialintelligence,the Company has expanded its technologicaladvantages since the release of Xunfei Spark Medical Model in 2023— the industry’s only healthcare large model trained on domesticallyproduced computing power — through the construction of high-quality datasets, development of hospital-specific models, and R&Dof medical AI agents. It has continuously made breakthroughs inkey technology areas such as evidence-based medical reasoningand health interaction, significantly improving the accuracy andprofessionalism of applications in medical settings, and maintaininga leading position in the industry for its core performance in keytasks within the healthcare sect